drugset / Trial / NCT00133757

Use of Pharmacotherapy to Reduce Cue-responsiveness in Smokers

NCT00133757

RandomizedParallel-groupDouble-blind

Summary

In this study we, the investigators at the Centre for Addiction and Mental Health, intend to explore whether bupropion is able to reduce smokers' responses to cigarette-related environmental cues, and craving. Previous studies have indicated that bupropion may be able to achieve these outcomes. Therefore, we predict that smokers treated with bupropion for several weeks will show reduced reactivity to cigarette cues and craving.

Timeline

Start
2005-06
Primary completion
Completion
2006-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Bupropion Small molecule 150 mg Oral

Indications